Scarica l'app Stockscreener
5.94
2.78%
-0.17
Dopo l'orario di chiusura:
5.96
0.02
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Ardelyx Inc Borsa (ARDX) Ultime notizie
Could Ardelyx’s New CMO Reframe ARDX’s Long-Term Nephrology Pipeline Strategy? - Sahm
Ardelyx, Inc. (ARDX) stock price, news, quote and history - Yahoo Finance UK
Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings? - Yahoo Finance
Ardelyx CMO Appointment Tests Growth Plans For Tenapanor Based Therapies - Yahoo Finance
Ardelyx names Rajani Dinavahi as CMO - The Pharma Letter
Ardelyx, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ardelyx (ARDX) CMO details 301,000 options at $6.11 and 201,000 shares - Stock Titan
Ardelyx President and CEO Sells 41,000 Shares for $243,000 - Yahoo Finance
Ardelyx President and CEO Sells 41,000 Shares for $243,000 - The Motley Fool
ARDX PE Ratio & Valuation, Is ARDX Overvalued - Intellectia AI
Assessing Ardelyx (ARDX) Valuation As New Chief Medical Officer Signals A Fresh Growth Phase - Sahm
Support Test: Is Ardelyx Inc stock forming a triangle pattern2026 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Ardelyx names Rajani Dinavahi as chief medical officer - Investing.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - The Manila Times
Ardelyx names Rajani Dinavahi as chief medical officer By Investing.com - Investing.com Canada
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Trading Action: Can Ardelyx Inc stock double in the next yearMarket Risk Summary & Community Verified Watchlist Alerts - baoquankhu1.vn
Tech Rally: Is Ardelyx Inc affected by consumer sentiment2026 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Ardelyx Investors Drop Appeal Over U-Turn on Medicare Program - Bloomberg Law News
ARDX Stock Price, Quote & Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
Ardelyx, Inc. Stock Hits Day Low of $5.26 Amid Price Pressure - Markets Mojo
[SCHEDULE 13G/A] ARDELYX, INC. Amended Passive Investment Disclosure - Stock Titan
Ardelyx Stock Gaps Down Amid Weak Start and Market Concerns - Markets Mojo
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - msn.com
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
ARDX stock is down pre-market after Q4 earnings miss, so why did this firm just hike price target by 80%? - MSN
Can Ardelyx Inc stock outperform in a bear market2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
ARDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock - MarketBeat
Raab, Ardelyx CEO, sells $243k in ARDX stock By Investing.com - Investing.com South Africa
Raab, Ardelyx CEO, sells $243k in ARDX stock - Investing.com
Ardelyx (ARDX) CEO exercises options, sells 41,666 shares under plan - Stock Titan
Ardelyx, Inc. Opens with 8.38% Gain, Contrasting Recent Performance Trends - Markets Mojo
Ardelyx, Inc. Hits Day High with Strong 14.49% Intraday Surge - Markets Mojo
Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments? - simplywall.st
Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026 - Meyka
Leerink Partners reiterates Ardelyx stock rating on pipeline progress - Investing.com
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - The Manila Times
Five kidney disease advocates honored for decades of patient support - Stock Titan
Breakout Move: How does Ardelyx Inc correlate with Nasdaq2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan - MarketBeat
Ardelyx at Leerink Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
ARDX: IBSRELA targets $1B sales by 2029, with pipeline and commercial growth fueled by strong execution - TradingView
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance
Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations - simplywall.st
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):